Business Context and Reporting Period
This Form 8-K is filed by NanoVibronix, Inc. (trading symbol: NAOV) on March 30, 2020. The filing addresses a delay in the submission of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The Company is an emerging growth company incorporated in Delaware with principal operations and manufacturing facilities located in Israel.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the procedural delay of the 10-K filing and the operational impacts of the COVID-19 pandemic.
Material Changes and Operational Disruptions
- 10-K Filing Delay: The Company is utilizing an SEC order to delay the 10-K filing due to COVID-19 disruptions. The new expected filing date is no later than May 14, 2020.
- Audit Delays: Staff and third-party auditors in Israel are working remotely due to government-mandated quarantines, significantly delaying the audit process for the year ended December 31, 2019.
- Manufacturing Disruptions: The Company's third-party manufacturer in China temporarily shut down for sixty days, causing significant delays in production and fulfillment of sales orders. Production of critical components remains uncertain.
- Regulatory Delays: A product design firm in Italy, required for CE mark compliance, has been shut down for over a month, delaying the 2020 CE mark approval submission.
- Workforce Reductions: The financial downturn has compelled the Company to furlough or reduce working hours for much of its operating staff and third-party contractors.
Outlook, Risks, and Management Commentary
Management highlights that the coronavirus outbreak poses a material adverse effect on operations, supply chains, and the global economy. Specific risks include:
- Supply Chain Interruption: Continued uncertainty regarding the completion of sub-assembly production in China and the availability of materials.
- Customer Cash Flow: Clients may encounter cash-flow issues, potentially delaying payments to the Company.
- Capital Markets: The outbreak may hamper the Company's ability to raise additional funds or sell securities.
- Market Disruption: The medical community's focus may shift to coping with the virus, disrupting the marketplace in which the Company operates.
The Company notes that the extent of the impact depends on future developments that are highly uncertain and cannot be predicted.
Investor Verification Checklist
- Verify the actual filing date of the Form 10-K for the year ended December 31, 2019, once submitted.
- Monitor the status of the third-party manufacturer in China to assess production recovery timelines.
- Review the updated 10-K for specific financial impacts regarding furloughs, reduced working hours, and delayed customer payments.
- Confirm the status of the CE mark approval submission given the delays in Italy.
- Assess the Company's liquidity position in light of potential delays in customer payments and the need for additional funding.